Get the Stockscreener App
32.15
2.10%
-0.69
After Hours:
32.15
Scholar Rock Holding Corp stock is traded at $32.15, with a volume of 1.69M.
It is down -2.10% in the last 24 hours and down -17.18% over the past month.
See More
Previous Close:
$32.84
Open:
$31.86
24h Volume:
1.69M
Relative Volume:
1.84
Market Cap:
$3.20B
Revenue:
$47.30M
Net Income/Loss:
$-225.97M
P/E Ratio:
-13.68
EPS:
-2.35
Net Cash Flow:
$-188.86M
1W Performance:
-4.91%
1M Performance:
-17.18%
6M Performance:
+301.37%
1Y Performance:
+81.02%
1-Day Range:
$30.79
$32.91
1-Week Range:
$30.79
$34.18
52-Week Range:
$6.76
$46.98
Scholar Rock Holding Corp Stock (SRRK) Company Profile
Name
Scholar Rock Holding Corp
Sector
Industry
Phone
857-259-3860
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare SRRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
32.15 | 3.20B | 47.30M | -225.97M | -188.86M | -2.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Reiterated | H.C. Wainwright | Buy |
| Oct-07-24 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-24 | Initiated | Raymond James | Strong Buy |
| Oct-25-23 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Overweight |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jul-12-22 | Initiated | Truist | Buy |
| Mar-23-22 | Initiated | H.C. Wainwright | Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Mar-12-20 | Initiated | Robert W. Baird | Outperform |
View All
Scholar Rock Holding Corp Stock (SRRK) Latest News
Teacher Retirement System of Texas Has $752,000 Stake in Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Sold by BIT Capital GmbH - MarketBeat
Corient Private Wealth LLC Takes $394,000 Position in Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
American Century Companies Inc. Buys Shares of 656,967 Scholar Rock Holding Co. (NASDAQ:SRRK) - MarketBeat
Raymond James Financial Inc. Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
Wedbush Reiterates Outperform Rating for Scholar Rock (NASDAQ:SRRK) - MarketBeat
Insider Selling: Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Sells 6,500 Shares of Stock - MarketBeat
Loomis Sayles & Co. L P Makes New Investment in Scholar Rock Holding Co. (NASDAQ:SRRK) - MarketBeat
Swiss National Bank Grows Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK) - MarketBeat
Victory Capital Management Inc. Invests $374,000 in Scholar Rock Holding Co. (NASDAQ:SRRK) - MarketBeat
Scholar Rock stock holds $45 target, buoyed by FDA priority review - Investing.com India
Scholar Rock (NASDAQ:SRRK) Given “Outperform” Rating at Wedbush - Defense World
Scholar Rock interim PFO sells $449k in stock By Investing.com - Investing.com South Africa
Scholar Rock chief commercial officer sells $215k in stock By Investing.com - Investing.com South Africa
Scholar Rock chief commercial officer sells $215k in stock - Investing.com
Scholar Rock interim PFO sells $449k in stock - Investing.com India
FDA accepts Scholar Rock BLA for apitegromab under priority review to treat SMA - TipRanks
Is It Time For Me To Buy Scholar Rock Holding Corp (NASDAQ: SRRK) Stock Now? - Stocks Register
CrowdStrike, Scholar Rock, Cloudflare - TradingView
Scholar Rock Gets US FDA Priority Review for Potential Spinal Muscular Atrophy Treatment - Marketscreener.com
FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy - MarketScreener
Swiss National Bank Boosts Stock Position in Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
Scholar Rock Holding Co. (NASDAQ:SRRK) Director Sells $34,626.52 in Stock - MarketBeat
AlphaQuest LLC Reduces Position in Scholar Rock Holding Co. (NASDAQ:SRRK) - MarketBeat
Victory Capital Management Inc. Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
Skandinaviska Enskilda Banken AB publ Purchases New Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) - MarketBeat
Proficio Capital Partners LLC Invests $2.37 Million in Scholar Rock Holding Co. (NASDAQ:SRRK) - MarketBeat
Charles Schwab Investment Management Inc. Boosts Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK) - MarketBeat
Scholar Rock (NASDAQ:SRRK) Given "Outperform" Rating at Wedbush - MarketBeat
Scholar Rock appoints Erin Moore as interim Principal Financial Officer -March 21, 2025 at 04:36 pm EDT - Marketscreener.com
Scholar Rock director Katie Peng sells $34,626 in stock - Investing.com India
Scholar Rock director Katie Peng sells $34,626 in stock By Investing.com - Investing.com UK
Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Sold by US Bancorp DE - Defense World
54,717 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Bought by Proficio Capital Partners LLC - Defense World
Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Acquired by Bank of New York Mellon Corp - MarketBeat
Scholar Rock’s (SRRK) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Charles Schwab Investment Management Inc. Purchases 119,616 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
Scholar Rock Holding Corp Stock (SRRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):